Showing 4741-4750 of 5000 results for "".
- Support Camp Discovery: Follow Us on Twitterhttps://practicaldermatology.com/news/20140130-support_camp_discovery_follow_us_on_twitter/2459354/Practical Dermatology® is excited to announce that we'll donate 20 cents for every new Twitter follower from Jan. 31, 2014 through March 14, 2014* to Camp Discovery. Simply follow @Practical_Derm on Twitte
- CeraVe Launches Two Skin Care Productshttps://practicaldermatology.com/news/20140123-cerave_launches_two_skin_care_products/2459361/CeraVe has introduced the CeraVe Eye Repair Cream and CeraVe Intensive Stretch Marks Cream. The Eye Repair Cream combines three essential ceramides, to help repair and restore the delicate barrier around the eyes, with hydrating hyaluronic acid to help diminish fine lines and wrinkles. The Intensive
- Alma Lasers Debuts its 2014 Webinar Serieshttps://practicaldermatology.com/news/20140116-alma_lasers_debuts_its_2014_webinar_series/2459372/In a complimentary webinar series, industry experts will showcase their success building local market awareness to drive practice results. Spearheaded by Alma Lasers , the informative ses
- Daniel Siegel, MD Appointed to Board of Directors for Caliber Imaging & Diagnosticshttps://practicaldermatology.com/news/20140113-daniel_siegel_md_appointed_to_cabilber_imaging__diagnostics_board_of_directors/2459374/Caliber Imaging & Diagnostics, formerly Lucid, Inc., appointed Daniel Mark Siegel, MD to its Board of Directors, effective immediately. This increases the number of Board members to eight. Dr. Siegel is Clinical Professor of Dermatology at SUNY Downstate Medical Center (State Univ
- NeXeption, LLC Forms New Company Alexar Therapeutics, Inc. to Develop Novel LXR Agonist Portfolio for Dermatologic Indicationshttps://practicaldermatology.com/news/20140102-nexeption_llc_forms_new_company_alexar_therapeutics_inc_to_develop_novel_lxr_agonist_portfolio_for_dermatologic_indications/2459383/NeXeption, LLC, a biopharmaceutical management company that brings together product opportunities, management expertise and funding to reach compelling partnership milestones, has secured $21.5 million in Series A financing to form Alexar Therapeutic
- Cutera Appoints Scott Ashworth as Executive Vice President of Global Saleshttps://practicaldermatology.com/news/20131230-cutera_appoints_scott_ashworth_as_executive_vice_president_of_global_sales/2459385/Scott Ashworth recently joined Cutera as Executive Vice President of Global Sales. He brings twenty-five years of experience in building and leading global sales and marketing teams focused on commercialization of products, establishing distributio
- Cosmetic Surgery Forum Kicks Off in Las Vegashttps://practicaldermatology.com/news/20131206-cosmetic_surgery_forum_kicks_off_in_las_vegas/2459397/The fifth annual Cosmetic Surgery Forum got underway yesterday in Las Vegas, Nevada, highlighted by varied educational sessions and discussion among faculty, attendees, and residents. Among the offerings from the first day were 75 resident presentations, practice management pearls, live injections,
- Investigational Melanoma Agent Improves Survival in Phase III Trialhttps://practicaldermatology.com/news/20131120-investigational_melanoma_agent_improves_survival_in_phase_iii_trial/2459408/Interim results from a pivotal Phase III trial show that Amgen's investigational agent talimogene laherpaepvec increased overall survival in patients with unresected stage IIIB, IIIC, or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF). The study found that median ov
- Data Indicate Need to Critically Assess Sunscreen Formulationshttps://practicaldermatology.com/news/20131107-data_indicate_need_to_critically_assess_sunscreen_formulations/2459419/When it comes to sunscreen selection, consumers may benefit from an assessment of a product's specific formulation rather than simply a “Broad Spectrum” claim, according to a poster presented at last month's Fall Clinical Dermatology Conference (Ouyang, et al.). The poster analyzed the critical wave
- FDA Clears Fish-Skin Technology to Heal Human Woundshttps://practicaldermatology.com/news/20131107-fda_clears_fish-skin_technology_to_heal_human_wounds/2459421/Kerecis Limited announced has received FDA 510(k) clearance from the Food and Drug Administration (FDA) to market a proprietary fish-skin, Omega3, tissue-regeneration technology for the treatment of chronic wounds in the US. The technology, marketed under the name MariGen Omega3, is indicated for th